



# CLINICAL GUIDELINES

## Oncology Medications Policy

Version 1.0

Effective February 14, 2020



eviCore healthcare Clinical Decision Support Tool Diagnostic Strategies: This tool addresses common symptoms and symptom complexes. Imaging requests for individuals with atypical symptoms or clinical presentations that are not specifically addressed will require physician review. Consultation with the referring physician, specialist and/or in

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright 2017 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in the CPT® book. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.

# Oncology Medications Policy

## Scope of Policy:

- All medications approved by the United States Food & Drug Administration (FDA) and used for the direct treatment of cancer are subject to governance within this document.
- All myeloid growth factors, antiemetic agents, bone modifying agents, erythropoiesis-stimulating agents, and somatostatin analogues approved by the FDA and used for the supportive treatment of cancer are subject to governance within this document.
  - ◆ All other medication uses for the supportive treatment of cancer are outside the scope of this policy.
- All oncology medication uses related to hematopoietic stem cell transplantation (including but not limited to mobilization, harvest, transplant, supportive care, and graft vs. host disease) are outside the scope of this policy.
- All medication uses that are not associated with the direct treatment of cancer or cancer-related symptoms are outside the scope of this policy.

## Section 1: Medications Used for Primary Treatment of Cancer:

eviCore recognizes all injectable, oral, and topical oncology medications listed for a specific oncologic direct treatment indication in the National Comprehensive Cancer Network (NCCN) Guidelines with Categories of Evidence and Consensus of 1, 2A, or 2B as evidence-based standards of care and medically necessary. The complete versions of the most recent NCCN Guidelines are available free of charge to the general public at <http://www.nccn.org>. Detailed descriptions of the methodology for establishing NCCN Categories of Evidence and Consensus can be found at: [https://www.nccn.org/professionals/physician\\_gls/categories\\_of\\_consensus.asp](https://www.nccn.org/professionals/physician_gls/categories_of_consensus.asp).

All U.S. Food and Drug Administration (FDA) approved medications used for direct cancer treatment not currently addressed in the NCCN guidelines will be recognized as medically necessary when used in accordance with the FDA indication. All drugs used for direct treatment of cancer require prior authorization unless listed as exempted in the “Prior Authorization NOT Required” Section 1a below.

## **Section 1a: Exempted Cancer Treatment Medications—Prior Authorization NOT Required**

<b>Drug Class</b>	<b>Exempted Drugs</b>
Hormonal agents	Ethinyl estradiol Levonorgestrel Medroxyprogesterone Tamoxifen
Antimetabolites	6-mercaptopurine (oral formulation) 6-thioguanine (oral formulation) Methotrexate (oral formulation)
Corticosteroids	Dexamethasone (oral and injectable formulations) Hydrocortisone (oral and injectable formulations) Methylprednisolone (injectable formulation) Prednisolone (oral formulation) Prednisone (oral formulation)
NSAIDs	Celecoxib Diclofenac sodium Sulindac
Antimicrobials	Doxycycline Ketoconazole
Antihypertensives	Doxazosin mesylate

## **Section 1b: Exceptions to NCCN Guidelines in Medications Used for Primary Treatment of Cancer:**

eviCore acknowledges that not all medically necessary treatments will conform to NCCN guidelines based on patient variability and unique clinical circumstances. Approximately 85% of primary treatment regimens authorized under the eviCore Medical Oncology solution have NCCN consensus support. The remaining 15% of regimen approvals primarily encompass rare cancers or subtypes not addressed by NCCN or clinically appropriate exceptions based on individual patient and/or disease factors. eviCore supports a highly efficient process to conduct thorough clinical review of all requested treatment regimens. A variety of additional standard references are used to determine medical necessity in these highly individualized cases. Common examples include peer-reviewed scientific articles, clinical practice guidelines from professional or medical specialty societies, coverage policies of government or commercial payers, FDA indications, and clinical expertise of experienced board-certified oncology practitioners provided through real-time peer consultation.

eviCore frequently performs utilization management as a delegate for commercial and government payers. For those delegated members, certain medications may have differing authorization requirements and specific health plan coverage policies that supersede this eviCore policy will be applied to determine medical necessity.

## **Section 2: Medications Used for Supportive Treatment of Cancer Patients:**

Medications approved by the United States Food & Drug Administration (FDA) that are used as supportive care in cancer treatment are subject to governance within this guideline document. Supportive care therapies can prevent and treat clinical symptoms that result from primary cancer treatment medications or from the disease itself. The supportive therapy classes included in this policy are myeloid growth factors, anti-emetics, erythropoietin stimulating agents, somatostatin analogues, and bone modifying agents. Uses that are not associated with treatment of cancer-related symptoms are outside of the scope of this policy.

eviCore recognizes all injectable, oral, and topical oncology medications listed for a specific oncologic supportive treatment indication in the National Comprehensive Cancer Network (NCCN) Guidelines with Categories of Evidence and Consensus of 1, 2A, or 2B as evidence-based standards of care and medically necessary. The complete versions of the most recent NCCN Guidelines are available free of charge to the general public at <http://www.nccn.org>. Detailed descriptions of the methodology for establishing NCCN Categories of Evidence and Consensus can be found at: [https://www.nccn.org/professionals/physician\\_gls/categories\\_of\\_consensus.asp](https://www.nccn.org/professionals/physician_gls/categories_of_consensus.asp).

All FDA-approved myeloid growth factors, anti-emetics, erythropoiesis-stimulating agents, somatostatin analogues, and bone modifying agents used as supportive care in cancer treatment that are not currently addressed in the NCCN guidelines will be recognized as medically necessary when used in accordance with the FDA indication. All drugs in the above listed classes require prior authorization unless listed as exempted in the “Prior Authorization NOT Required” Section 2a below.

### **Section 2a: Exempted Supportive Medications—Prior Authorization NOT Required**

<b>Supportive Medication Group</b>	<b>Exempted Drugs and/or Classes</b>
Antiemetic Therapies	Generic ondansetron (oral and injectable formulations) Generic granisetron (oral and injectable formulations) Generic aprepitant (oral formulation) Corticosteroids (all drugs in class) Benzodiazepines (all drugs in class) Phenothiazines (all drugs in class) Atypical and typical antipsychotics (all drugs in class) Cannabinoids (all drugs in class) Metoclopramide Anticholinergics (all drugs in class)
Bone Modifying agents	Alendronate Pamidronate
Erythropoiesis-Stimulating Agents	No exempted medications
Myeloid Growth Factors	No exempted medications
Somatostatin analogues	No exempted medications

## **Section 2b: Exceptions to NCCN Guidelines for Medications Used for Supportive Treatment of Cancer:**

eviCore acknowledges that not all medically necessary and clinically appropriate treatments will conform to NCCN guidelines based on patient variability and unique clinical circumstances. Approximately 95% of supportive medications authorized under the eviCore Medical Oncology solution have NCCN consensus support. The remaining 5% of regimen approvals primarily encompass clinically appropriate exceptions based on individual patient and disease factors. eviCore supports a highly efficient process to conduct thorough clinical review of all requested treatment regimens. A variety of additional standard references are used to determine medical necessity in these highly individualized cases. Common examples include peer-reviewed scientific articles, clinical practice guidelines from professional or medical specialty societies, coverage policies of government or commercial payers, FDA indications, and clinical expertise of experienced board-certified oncology practitioners provided through real-time peer consultation.

eviCore frequently performs utilization management as a delegate for commercial and government payers. For those delegated members, certain medications may have differing authorization requirements and specific health plan coverage policies that supersede this eviCore policy will be applied to determine medical necessity.

## **Section 3: eviCore Oncology Medication Guideline Methodology:**

eviCore's Oncology Medication Policy is developed by specialty-focused oncology pharmacists and board-certified oncologists and is then reviewed and approved by eviCore's Medical Advisory Committee on at least an annual basis. Additionally, eviCore's oncology pharmacists and board-certified oncologists collaboratively develop and maintain highly specific and up-to-date algorithms translated from the NCCN Guidelines. All new and revised algorithms are critically reviewed and approved by NCCN to ensure concordance with the Guidelines prior to implementation for medical necessity determination uses. By evaluating clinical, pathologic, radiologic, genetic, and molecular findings for an individual patient, NCCN-recommended single and/or multidrug regimen options are rapidly determined through an efficient decision support process that can be completed in as little as three minutes via web-based or telephonic tools.

eviCore conducts ongoing monitoring of the drug pipeline and incorporates new FDA-approved therapies or expanded indications into the Medical Oncology solution almost immediately after the approval date. The development of the NCCN Guidelines is an ongoing and iterative process, which is based on a critical review of the best available evidence and derivation of recommendations by a multidisciplinary panel of experts in the field of cancer. In addition to scheduled annual updates, NCCN frequently releases interim real-time guideline updates to incorporate recent critical advancements in the field of cancer research and management. eviCore collaborates closely with NCCN to ensure that the eviCore Medical Oncology algorithms are updated rapidly following the release of an update to any NCCN Guideline.

## **About NCCN:**

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are comprised of recommendations for the prevention, diagnosis, and management of malignancies across the continuum of care. The NCCN Guidelines currently apply to more than 97% of patients living with cancer in the United States. The guidelines are developed and updated by 54 individual panels, comprising more than 1275 clinicians and oncology researchers from the 27 NCCN member institutions. All information provided by the NCCN is referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) ©2019 National Comprehensive Cancer Network. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines free of charge, go online to [www.NCCN.org](http://www.NCCN.org).

### ***Reference***

1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)  
[https://www.nccn.org/professionals/physician\\_gls/default.aspx](https://www.nccn.org/professionals/physician_gls/default.aspx)

\*All information provided by the NCCN is "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) © 2019 National Comprehensive Cancer Network. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org."